Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Guided Therapeutics Inc (OP:GTHP)

0.2400 +0.0100 (+4.35%)

Streaming Delayed Price Updated: 3:53 PM EDT, Apr 1, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	15,851
Open	0.2300
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	0.2300
Today's Range	0.2206 - 0.2400
52wk Range	0.0644 - 0.5400
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Guided Therapeutics Provides Updates on FDA Application Study Results, 2025 Earnings Increase and Successful Warrant Offering

March 31, 2026

From Guided Therapeutics, Inc.

Via Business Wire

Analysis of Guided Therapeutics' FDA Study Data Reveals Compelling Clinical Need for LuViva

December 17, 2025

From Guided Therapeutics, Inc.

Via Business Wire

Performance

YTD	-55.6%	-55.6%
1 Month	-31.4%	-31.4%
3 Month	-40.0%	-40.0%
6 Month	N/A	N/A
1 Year	+187.1%	+187.1%

More News

Guided Therapeutics Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor

December 11, 2025

From Guided Therapeutics, Inc.

Via Business Wire

Guided Therapeutics Inks Initial $200,000 Deal with New Distribution Partner Yuanshuo Medical Instruments Corporation

November 19, 2025

From Guided Therapeutics, Inc.

Via Business Wire

Guided Therapeutics Receives $70,000 -- Its Second of Nine Payments Totaling $700,000 -- from New Chinese Distribution Partner that Provides Products for 2 Million Annual Cervical Cancer Screenings

August 19, 2025

From Guided Therapeutics, Inc.

Via Business Wire

Guided Therapeutics Provides Update on Completion of US FDA Clinical Trial

August 13, 2025

From Guided Therapeutics, Inc.

Via Business Wire

Guided Therapeutics Makes Initial Shipment to New Chinese Distribution Partner Hangzhou Dongye Medical Technology, Ltd.

July 02, 2025

From Guided Therapeutics, Inc.

Via Business Wire

Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor

June 10, 2025

From Guided Therapeutics, Inc.

Via Business Wire

Guided Therapeutics Receives $100,000 from SMI’s Investment Partners to Continue Commercialization Process of LuViva in China

May 27, 2025

From Guided Therapeutics, Inc.

Via Business Wire

Guided Therapeutics Receives Order and Full Payment From Indonesia for 4 LuViva Systems and 1,200 Disposables

December 10, 2024

From Guided Therapeutics, Inc.

Via Business Wire

Guided Therapeutics Announces Filing of Application for NMPA Approval to Market and Sell LuViva in China

October 22, 2024

From Guided Therapeutics, Inc.

Via Business Wire

Guided Therapeutics’ Announces Data from Chinese NMPA Clinical Study Signed Off by All Four Clinical Sites With Better Than Expected Results

July 10, 2024

From Guided Therapeutics, Inc.

Via Business Wire

Leading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial Results

February 20, 2024

From Guided Therapeutics, Inc.

Via Business Wire

Guided Therapeutics Announces Completion of Clinical Study for Chinese Regulatory Approval

November 20, 2023

From Guided Therapeutics, Inc.

Via Business Wire

Guided Therapeutics Provides Update on Start of Clinical Trial for US FDA Approval

May 01, 2023

From Guided Therapeutics, Inc.

Via Business Wire

Guided Therapeutics Announces New Agreement and Purchase Orders from Shandong Yaohua Medical Instrument Corporation

March 15, 2023

From Guided Therapeutics, Inc.

Via Business Wire

Guided Therapeutics Signs Agreement to Begin Clinical Trial for US FDA Approval

December 21, 2022

From Guided Therapeutics, Inc.

Via Business Wire

Guided Therapeutics Provides Update of Significant Progress in Chinese Clinical Study for Marketing Approval of the LuViva Advanced Cervical Scan

November 09, 2022

From Guided Therapeutics, Inc.

Via Business Wire

Guided Therapeutics Closes $3.3 Million Bridge Financing

September 07, 2022

From Guided Therapeutics, Inc.

Via Business Wire

Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva® Advanced Cervical Scan

July 20, 2022

From Guided Therapeutics, Inc.

Via Business Wire

Guided Therapeutics Announces Testing Completion of First 150 Patients in Chinese Clinical Study and Receives Milestone Payment of $177,740

March 31, 2022

From Guided Therapeutics, Inc.

Via Business Wire

Guided Therapeutics Announces Start of Chinese Clinical Trial for Approval to Market and Sell LuViva in China

November 17, 2021

From Guided Therapeutics, Inc.

Via Business Wire

Guided Therapeutics Ships LuViva Devices to China for Start of Clinical Trial; Receives Additional $100,000 Payment

October 05, 2021

From Guided Therapeutics, Inc.

Via Business Wire

Guided Therapeutics Receives Notification of Successful Clinical Trial Regulatory Review and $133,000 Payment from China

August 19, 2021

From Guided Therapeutics, Inc.

Via Business Wire

New European Published Study Shows LuViva Detects 20% More Precancerous and Cancerous Cervical Disease than HPV Test

July 28, 2021

From Guided Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is Guided Therapeutics Inc publicly traded?

Yes, Guided Therapeutics Inc is publicly traded.

What exchange does Guided Therapeutics Inc trade on?

Guided Therapeutics Inc trades on the OTC Traded

What is the ticker symbol for Guided Therapeutics Inc?

The ticker symbol for Guided Therapeutics Inc is GTHP on the OTC Traded

What is the current price of Guided Therapeutics Inc?

The current price of Guided Therapeutics Inc is 0.2400

When was Guided Therapeutics Inc last traded?

The last trade of Guided Therapeutics Inc was at 04/01/26 03:53 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.